Catalyst
Slingshot members are tracking this event:
Head-to-Head Study of CMX157 vs. Viread for Treating Hepatitis B expected to conclude in the fourth quarter of 2016
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| CTRV | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 13, 2016
Occurred Source:
http://ir.contravir.com/2016-10-13-CMX157-Demonstrates-99-Viral-Load-Reduction-in-Ongoing-Head-to-Head-Phase-2a-Clinical-Study-Vs-Viread-in-Hepatitis-B-Patients
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Cmx157, Viread, Hepatitis B, Hbv Infection, Tdf, Tenofovir, Viread
